Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000674426 | SCV000799762 | likely pathogenic | Ellis-van Creveld syndrome | 2018-05-04 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001861843 | SCV002123097 | pathogenic | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2023-10-29 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Glu179*) in the EVC2 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in EVC2 are known to be pathogenic (PMID: 17024374, 19810119, 19876929). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with EVC2-related conditions. ClinVar contains an entry for this variant (Variation ID: 558195). For these reasons, this variant has been classified as Pathogenic. |
Ambry Genetics | RCV002532163 | SCV003536789 | pathogenic | Inborn genetic diseases | 2021-10-08 | criteria provided, single submitter | clinical testing | The c.534dupT (p.E179*) alteration, located in exon 5 (coding exon 5) of the EVC2 gene, consists of a duplication of T at position 534, causing a translational frameshift with a predicted alternate stop codon after amino acids. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. Based on the supporting evidence, this variant is expected to be causative of autosomal recessive Ellis-van Creveld syndrome (AR); however, its clinical significance for autosomal dominant Weyers acrofacial dysostosis (AD) is unclear. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). Based on the available evidence, this alteration is classified as pathogenic. |